Highest-materiality recent filing
Agios Q1 mitapivat revenue $20.7M; 242 AQVESME scrips; sCD sNDA plan in Q2
Worldwide mitapivat net revenue $20.7M in Q1 2026, up from $8.7M in Q1 2025.
Agios Q4 net loss $108M; AQVESME approved for thalassemia, U.S. launch started
PYRUKYND worldwide net revenue $20M in Q4 ($16M U.S., $4M ex-U.S.), up 49% YoY in U.S.
AQVESME (mitapivat) U.S. approval in thalassemia Dec 2025; commercial launch underway, product available late Jan 2026.
Agios Q3 PYRUKYND rev $12.9M (+44% YoY); net loss $103.4M; thalassemia PDUFA Dec 7
Q3 PYRUKYND net revenue $12.9M (+44% YoY vs $9.0M); 149 U.S. patients on therapy.
Analyst report on Aug 4, 2025 references four FAERS cases; Agios says benefit-risk profile unchanged.
Agios Q2 2025 net loss $112M; PYRUKYND revenue $12.5M; PDUFA Sept 7 for thalassemia
Net loss $112.0M vs $96.1M YoY; PYRUKYND net revenue $12.5M, up from $8.6M in Q2 2024.
Agios Pharmaceuticals elects Jay Backstrom, M.D., MPH to board
Dr. Backstrom appointed as Class III director, term until 2028 Annual Meeting.
Agios shareholders elect two directors, approve 2.5M share plan increase and say-on-pay
Class III directors Jacqualyn A. Fouse and David Scadden elected with 45.96M and 46.20M votes for, respectively.
Agios Q1 PYRUKYND revenue $8.7M; PDUFA Sept 7 for thalassemia; net loss $89.3M
PYRUKYND net revenue $8.7M in Q1 2025 vs $8.2M in Q1 2024; 136 patients on therapy.
Agios board member David Schenkein resigns effective Feb 28, 2025; stays as strategic advisor
Dr. Schenkein notified company of resignation from board on Feb 10, 2025, effective Feb 28, 2025.
Agios Q4: PYRUKYND revenue $10.7M, mitapivat PDUFA Sept 7, 2025; cash $1.5B
PYRUKYND net revenue $10.7M in Q4 (+20% QoQ), full year $36.5M vs $26.8M in 2023.
Agios announces 2025 milestones: PYRUKYND PDUFA Sept 7; RISE UP topline in late 2025
FDA accepted sNDA for PYRUKYND in thalassemia; PDUFA goal date September 7, 2025.
FDA adds liver injury warning to PYRUKYND label for PK deficiency
FDA approved update to PYRUKYND USPI: liver injury observed in patients with another condition at higher doses.
Agios reports Q3 net income of $947.9M on $1.1B milestone payments; PYRUKYND rev $9.0M
Net income $947.9M vs loss $91.3M YoY; driven by $1.1B payments from Royalty Pharma & Servier.
Agios Q2 2024 net loss $96.1M; PYRUKYND rev $8.6M; plans thalassemia sNDA by year-end
PYRUKYND net revenue $8.6M in Q2 2024, up 5% sequentially; 128 patients on therapy.
Elected Kaye Foster (45.8M for, 5.3M withheld), Maykin Ho (46.7M for, 4.4M withheld), Jeffrey Capello (47.8M for, 3.3M withheld), Catherine Owen (45.6M for, 5.5M withheld) as Class II directors.
Agios sells vorasidenib royalty rights to Royalty Pharma for $905M upfront upon FDA approval
Royalty Pharma pays $905M to Agios upon FDA approval of vorasidenib (PDUFA date Aug 20, 2024).
Agios Q1 2024 PYRUKYND revenue $8.2M; net loss $81.5M; mitapivat ENERGIZE-T readout Q2
PYRUKYND net revenue $8.2M in Q1 2024, up 15% sequentially; 120 patients on therapy.
On February 10, 2025, David P. Schenkein, M.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective February 28, 2025.
Max materiality 0.85 · Median 0.68 · Most common event earnings